Blue Steens in July 2020

Check out my latest monthly review! It showcases Blue Steens’ latest posts, some news from biopharma & medtech as well as interesting events I have attended or noticed. At a glance In terms of COVID-19, hydroxychloroquine as a potential treatment has fallen further from favour whilst remdesivir is in high demand; dexamethasone has also stood its ground; 4 highly promising […]

Blue Steens in June 2020

Check out my latest monthly review! It showcases Blue Steens’ latest posts, some news from biopharma & medtech as well as interesting events I have attended or noticed. At a glance In terms of COVID-19, we’ve seen interesting technologies being added to the spectrum of testing capabilities; hydroxychloroquine as a potential treatment seems to be falling from favour whilst remdesivir […]

Blue Steens in May 2020

Check out my latest monthly review! It showcases Blue Steens’ latest posts, some news from biopharma & medtech as well as interesting events I have attended or noticed. At a glance We’ve seen more reliable COVID-19 serological tests coming out on the market as well as clinical trials commencing and early results being released. Quite a few virtual events have […]

The winding path from lab to patient

Despite potential short-cuts, drug development is a lengthy and risky process that culminates in marketing approval. However, just because a drug achieves regulatory approval, does not mean that it will be instantly available to those in need. The complex journey for a pharmaceutical to gain patient access continues.